Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries.

Mooney J, Chang E, Lalla D, Papoyan E, Raimundo K, Reddy SR, Stauffer J, Yan T, Broder MS.

Ann Am Thorac Soc. 2019 Jan 8. doi: 10.1513/AnnalsATS.201806-376RL. [Epub ahead of print] No abstract available.


Long Non-coding RNAs Are Central Regulators of the IL-1β-Induced Inflammatory Response in Normal and Idiopathic Pulmonary Lung Fibroblasts.

Hadjicharalambous MR, Roux BT, Feghali-Bostwick CA, Murray LA, Clarke DL, Lindsay MA.

Front Immunol. 2018 Dec 11;9:2906. doi: 10.3389/fimmu.2018.02906. eCollection 2018.


South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Barratt SL, Mulholland S, Al Jbour K, Steer H, Gutsche M, Foley N, Srivastava R, Sharp C, Adamali HI.

Front Pharmacol. 2018 Dec 17;9:1480. doi: 10.3389/fphar.2018.01480. eCollection 2018.


Determination of A Novel Antifibrotic Small Molecule GDC-3280 in Human Plasma and Urine by Liquid Chromatography Tandem Mass Spectrometry to Support Its First-in-human Clinical Trial.

Wang J, Van Parys M, Pan L, Chen Y, Cheung D, McKnight J, Milanowski D, Ding X, Dean B.

Biomed Chromatogr. 2019 Jan 7:e4482. doi: 10.1002/bmc.4482. [Epub ahead of print]


Casting a Spotlight on the Right Ventricle in Systemic Sclerosis.

Hsu S.

Arthritis Rheumatol. 2019 Jan 7. doi: 10.1002/art.40806. [Epub ahead of print]


Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL.

EBioMedicine. 2019 Jan 4. pii: S2352-3964(18)30629-7. doi: 10.1016/j.ebiom.2018.12.052. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center